Vyne Therapeutics Stock Today
| VYNE Stock | USD 1.77 0.01 0.57% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Vyne Therapeutics is trading at 1.77 as of the 20th of March 2025, a 0.57 percent increase since the beginning of the trading day. The stock's lowest day price was 1.74. Vyne Therapeutics has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of January 2018 | Category Healthcare | Classification Health Care |
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Vyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.75 M outstanding shares of which 139.81 K shares are at this time shorted by private and institutional investors with about 1.23 trading days to cover. More on Vyne Therapeutics
Moving together with Vyne Stock
Moving against Vyne Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vyne Stock Highlights
| President CEO | David Domzalski | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVyne Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vyne Therapeutics' financial leverage. It provides some insight into what part of Vyne Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vyne Therapeutics (VYNE) is traded on NASDAQ Exchange in USA. It is located in 685 Route 202/206 N, Bridgewater, NJ, United States, 08807 and employs 13 people. Vyne Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 44.25 M. Vyne Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.75 M outstanding shares of which 139.81 K shares are at this time shorted by private and institutional investors with about 1.23 trading days to cover.
Vyne Therapeutics currently holds about 42.81 M in cash with (33.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74.
Check Vyne Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Vyne Therapeutics is $44.25 Million. Over half of Vyne Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Vyne Ownership Details
Vyne Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 135 K | |
| Blackrock Inc | 2024-12-31 | 83.3 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 70.8 K | |
| Springbok Capital Management, Llc | 2024-12-31 | 59.4 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 37 K | |
| Royal Bank Of Canada | 2024-12-31 | 25.2 K | |
| Renaissance Technologies Corp | 2024-12-31 | 24.9 K | |
| Northern Trust Corp | 2024-12-31 | 24 K | |
| Xtx Topco Ltd | 2024-12-31 | 21 K | |
| Eventide Asset Management, Llc | 2024-12-31 | 1.4 M | |
| Cormorant Asset Management, Llc | 2024-12-31 | 1.4 M |
Vyne Therapeutics Historical Income Statement
Vyne Stock Against Markets
Vyne Therapeutics Corporate Management
| Russell DPhil | VP Devel | Profile | |
| Iain Stuart | Chief Officer | Profile | |
| MS MD | Consultant | Profile | |
| Subhashis MD | Senior Development | Profile | |
| David Schuz | VP Property | Profile | |
| Faad MD | Consultant | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth 0.467 | Return On Assets | Return On Equity |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.